Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage PYL
- Development stage
- Preclinical
- Lead developer
- University of Karachi
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
`bacteriophage PYL` (also referred to as `phage P¥L`) is a lytic bacteriophage isolated and characterized by researchers at the International Center for Chemical and Biological Sciences, University of Karachi. It specifically targets carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), a major pathogen associated with community-acquired skin and soft tissue infections, particularly burn wound infections. While monotherapy with bacteriophage PYL shows moderate lytic activity, it is susceptible to the emergence of resistant bacterial clones. However, when used in combination with the carbapenem antibiotic meropenem, bacteriophage PYL exhibits strong synergistic antibacterial activity (phage-antibiotic synergy), significantly reducing the minimum inhibitory concentration of meropenem, disrupting biofilms, and accelerating wound healing and bacterial clearance in burn wound infection models.
- Other names
- bacteriophage P¥Lphage PYLphage P¥L
Beyond the preview
Go deeper on bacteriophage PYL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage PYL.